Market capitalization | $136.17m |
Enterprise Value | $144.21m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.82 |
P/S ratio (TTM) P/S ratio | 5.50 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -41.19% |
Revenue (TTM) Revenue | $24.78m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:
2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 25 25 |
41%
41%
|
|
Gross Profit | 11 11 |
31%
31%
|
|
EBITDA | -21 -21 |
20%
20%
|
EBIT (Operating Income) EBIT | -24 -24 |
15%
15%
|
Net Profit | -60 -60 |
79%
79%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.
Head office | United States |
CEO | Charles Mills |
Employees | 54 |
Founded | 2015 |
Website | www.elutia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.